Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Valvular Atrial Fibrillation Clear all
Completed Phase 3 Interventional Results available

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

NCT02362659
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

NCT01896297
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pradaxa, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Hot Springs, Arkansas • Fremont, California • Moreno Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

NCT03061006
View directory record Official record
Conditions
Dementia, Cognition Disorders, Cerebral Ischemic Events
Interventions
Dabigatran Etexilate, Warfarin
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
65 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

NCT04956978
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Patient Decision Support Tool
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Suspended Not applicable Interventional

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

NCT06168942
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
Interventions
Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Active, not recruiting Not applicable Interventional

An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation

NCT05565599
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Left Atrial Appendage Closure
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Tucson, Arizona • Jonesboro, Arkansas • La Jolla, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

NCT00742859
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
betrixaban, Warfarin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational

Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure

NCT03508271
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
65 Years and older
Enrollment
60,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 23, 2026, 10:46 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of CIRC Technologies

NCT05654272
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2042
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Terminated Phase 3 Interventional Results available

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

NCT03839355
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology

NCT02702271
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
WATCHMAN FLX
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational

Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation

NCT03719144
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Jul 23, 2026, 10:46 PM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jul 23, 2026, 10:46 PM EDT
Terminated Phase 4 Interventional Results available

EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

NCT02561897
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Edoxaban, Warfarin
Drug
Lead sponsor
Electrophysiology Research Foundation
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Warren Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational

Real-world Dosing Patterns of Rivaroxaban in the United States

NCT03242278
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12,507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm

NCT03515083
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
Alive Cor Kardia mobile electrocardiogram monitor
Device
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

NCT00504556
View directory record Official record
Conditions
Atrial Fibrillation, Thromboembolism
Interventions
Edoxaban (DU-176b), warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
22
States / cities
Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 23, 2026, 10:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The CONFORMAL Early Feasibility Study

NCT03616028
View directory record Official record
Conditions
Non-valvular Atrial Fibrillation
Interventions
left atrial appendage closure
Device
Lead sponsor
Conformal Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
11
States / cities
Jonesboro, Arkansas • Santa Monica, California • Manchester, New Hampshire + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 23, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

NCT02100228
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Jul 23, 2026, 10:46 PM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

NCT02061748
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Observational
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 89 Years
Enrollment
38,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 23, 2026, 10:46 PM EDT